@article{78d736234fe048628e9e97fdd48686c5,
title = "Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research",
author = "Strawn, {Jeffrey R.} and Croarkin, {Paul E.}",
note = "Funding Information: Dr. Strawn has received research support from Edgemont, Eli Lilly, Shire, Forest Research Institute, Lunbeck, Neuronetics, and the National Institute of Health (NIMH and NIEHS). He receives royalties from Springer Publishing for two texts and has received material support from Assurex. Dr. Croarkin has received research support from Pfizer for an investigator-initiated study, Mayo Clinic Foundation, the Brain and Behavior Research Foundation, and NIMH. He has received material support from Assurex and Neuro-netics for investigator-initiated studies. He is the primary investigator for a multicenter trial sponsored by Neuronetics. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",
year = "2018",
month = jun,
doi = "10.1089/cap.2018.0012",
language = "English (US)",
volume = "28",
pages = "363",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "5",
}